Skip to main content
Erschienen in: AIDS and Behavior 3/2006

01.05.2006 | Original Paper

Monitoring Adherence to HIV Antiretroviral Therapy in Routine Clinical Practice: The Past, the Present, and the Future

verfasst von: David R. Bangsberg

Erschienen in: AIDS and Behavior | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Excerpt

Adherence to antiretroviral therapy is the strongest predictor of viral suppression, drug resistance, disease progression and death in HIV infected individuals (Bangsberg et al., 2000, 2003; Bangsberg, Hecht et al., 2001; Bangsberg, Perry et al., 2001; de Olalla et al., 2002; Hogg et al., 2002; Paterson et al., 2000). There is, however, no standard approach to adherence assessment in routine clinical practice. This situation is analogous to the general internist managing hypertension with out a blood pressure cuff or the critical care specialist managing a ventilator without measures of oxygenation. Worse yet, providers in routine clinical practice have rarely predicted adherence better than random (Bangsberg, Hecht et al., 2001; Bangsberg, Perry et al., 2001; Gross, Bilker, Friedman, Coyne, and Strom, 2002) which means that we are leaving the most critical determinant of HIV treatment outcomes to chance. …
Literatur
Zurück zum Zitat Artinian, N.T., Harden, J.K., Kronenberg, M.W., Vander Wal, J.S., Daher, E., & Stephens, Q. (2003). Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung, 32(4), 226–233.PubMedCrossRef Artinian, N.T., Harden, J.K., Kronenberg, M.W., Vander Wal, J.S., Daher, E., & Stephens, Q. (2003). Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung, 32(4), 226–233.PubMedCrossRef
Zurück zum Zitat Bangsberg, D.R., Acosta, E., Gupta, R., Guzman, D., Riley, E.D., & Harrigan, P.R. (2005). Differences in protease and non-nucleoside reverse transcriptase inhibitor adherence-resistance relationships are explained by virologic fitness. AIDS, 20(2), 223–231.CrossRef Bangsberg, D.R., Acosta, E., Gupta, R., Guzman, D., Riley, E.D., & Harrigan, P.R. (2005). Differences in protease and non-nucleoside reverse transcriptase inhibitor adherence-resistance relationships are explained by virologic fitness. AIDS, 20(2), 223–231.CrossRef
Zurück zum Zitat Bangsberg, D.R., Bronstone, A., Chesney, M.A., & Hecht, F.M. (2002). Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. Journal Acquired Immune Deficiency Syndrome, 31(Suppl. 3), S107–S111. Bangsberg, D.R., Bronstone, A., Chesney, M.A., & Hecht, F.M. (2002). Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. Journal Acquired Immune Deficiency Syndrome, 31(Suppl. 3), S107–S111.
Zurück zum Zitat Bangsberg, D.R., Charlebois, E.D., Grant, R.M., Holodniy, M., Deeks, S.G., & Perry, S. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17(13), 1925–1932.PubMedCrossRef Bangsberg, D.R., Charlebois, E.D., Grant, R.M., Holodniy, M., Deeks, S.G., & Perry, S. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17(13), 1925–1932.PubMedCrossRef
Zurück zum Zitat Bangsberg, D.R., Hecht, F., Clague, H., Charlebois, E., Ciccarone, D., & Chesney, M. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435–442.PubMed Bangsberg, D.R., Hecht, F., Clague, H., Charlebois, E., Ciccarone, D., & Chesney, M. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435–442.PubMed
Zurück zum Zitat Bangsberg, D.R., Hecht, F.M., Charlebois, E.D., Zolop, A.R., Holodniy, M., & Sheiner, L. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357–366.PubMedCrossRef Bangsberg, D.R., Hecht, F.M., Charlebois, E.D., Zolop, A.R., Holodniy, M., & Sheiner, L. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357–366.PubMedCrossRef
Zurück zum Zitat Bangsberg, D.R., Perry, S., Charlebois, E.D., Clark, R.A., Roberston, M., & Zolopa, A.R. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181–1183.PubMedCrossRef Bangsberg, D.R., Perry, S., Charlebois, E.D., Clark, R.A., Roberston, M., & Zolopa, A.R. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181–1183.PubMedCrossRef
Zurück zum Zitat Bova, C.A., Fennie, K.P., Knafl, G.J., Dieckhaus, K.D., Watrous, E., & Williams, A.B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS Behavior, 9(1), 103–110.CrossRef Bova, C.A., Fennie, K.P., Knafl, G.J., Dieckhaus, K.D., Watrous, E., & Williams, A.B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS Behavior, 9(1), 103–110.CrossRef
Zurück zum Zitat de Olalla, G., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J.L., & Cayla, J.A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal Acquired Immune Deficiency Syndrome, 30(1), 105–110.CrossRef de Olalla, G., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J.L., & Cayla, J.A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal Acquired Immune Deficiency Syndrome, 30(1), 105–110.CrossRef
Zurück zum Zitat Gross, R., Bilker, W.B., Friedman, H.M., Coyne, J.C., & Strom, B.L. (2002). Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS, 16(13), 1835–1837.PubMedCrossRef Gross, R., Bilker, W.B., Friedman, H.M., Coyne, J.C., & Strom, B.L. (2002). Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS, 16(13), 1835–1837.PubMedCrossRef
Zurück zum Zitat Gross, R., Zhang, Y., & Grossberg, R. (2005). Medication refill logistics and refill adherence in HIV. Pharmacoepidemiology and Drug Safety. Gross, R., Zhang, Y., & Grossberg, R. (2005). Medication refill logistics and refill adherence in HIV. Pharmacoepidemiology and Drug Safety.
Zurück zum Zitat Hogg, R., Heath, K., Bangsberg, D.R., Yip, B., Press, N., & O’Shaughnessy, M.V. (2002). Intermittent use of Triple Combination Therapy is Predictive of Mortality at Baseline and after one year of follow-up AIDS. AIDS, 16, 1051–1058.PubMedCrossRef Hogg, R., Heath, K., Bangsberg, D.R., Yip, B., Press, N., & O’Shaughnessy, M.V. (2002). Intermittent use of Triple Combination Therapy is Predictive of Mortality at Baseline and after one year of follow-up AIDS. AIDS, 16, 1051–1058.PubMedCrossRef
Zurück zum Zitat Jauhar, S. (2006). The demise of the physical exam. New England Journal of Medicine, 354(6), 548–551.PubMedCrossRef Jauhar, S. (2006). The demise of the physical exam. New England Journal of Medicine, 354(6), 548–551.PubMedCrossRef
Zurück zum Zitat King, M.S., Brun, S.C., & Kempf, D.J. (2005). Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. Journal of Infectious Diseases, 191(12), 2046–2052.PubMedCrossRef King, M.S., Brun, S.C., & Kempf, D.J. (2005). Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. Journal of Infectious Diseases, 191(12), 2046–2052.PubMedCrossRef
Zurück zum Zitat Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., & Arici, C. (2005). Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40(1), 158–163.PubMedCrossRef Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., & Arici, C. (2005). Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40(1), 158–163.PubMedCrossRef
Zurück zum Zitat Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115–1121.PubMedCrossRef Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115–1121.PubMedCrossRef
Zurück zum Zitat Parienti, J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., & Larouzé, B. (2004). Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine or Efavirenz-Based Antiretroviral Therapy. CID, 38, 1311–1316.CrossRef Parienti, J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., & Larouzé, B. (2004). Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine or Efavirenz-Based Antiretroviral Therapy. CID, 38, 1311–1316.CrossRef
Zurück zum Zitat Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., & Squier, C. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medcine, 133(1), 21–30. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., & Squier, C. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medcine, 133(1), 21–30.
Zurück zum Zitat Ruskin, P., Van der Wende, J., Clark, C., Fenton, J., Deveau, J., & Thapar, R. (2003). Feasibility of using the Med-eMonitor System in the treatment of Schizophrenia: A pilot study. Drug Information Journal, 37(3), 283–291. Ruskin, P., Van der Wende, J., Clark, C., Fenton, J., Deveau, J., & Thapar, R. (2003). Feasibility of using the Med-eMonitor System in the treatment of Schizophrenia: A pilot study. Drug Information Journal, 37(3), 283–291.
Zurück zum Zitat Simoni, J., Kurth, A., Pearson, C., Pantalone, D., Merrill, J., & Frick, P. (2006). Self-reported measures of antiretroviral therapy adherence. Aids and Behavior. Simoni, J., Kurth, A., Pearson, C., Pantalone, D., Merrill, J., & Frick, P. (2006). Self-reported measures of antiretroviral therapy adherence. Aids and Behavior.
Zurück zum Zitat Spacek, L.A., Shihab, H.M., Kamya, M.R., Mwesigire, D., Ronald, A., Mayanja, H., et al. (2006). Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases, 42(2), 252–259.PubMedCrossRef Spacek, L.A., Shihab, H.M., Kamya, M.R., Mwesigire, D., Ronald, A., Mayanja, H., et al. (2006). Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases, 42(2), 252–259.PubMedCrossRef
Zurück zum Zitat Weiser, S.D., Guzman, D., Riley, E.D., Clark, R., & Bangsberg, D.R. (2004). Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clinical Trials, 5(5), 278–287.PubMedCrossRef Weiser, S.D., Guzman, D., Riley, E.D., Clark, R., & Bangsberg, D.R. (2004). Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clinical Trials, 5(5), 278–287.PubMedCrossRef
Metadaten
Titel
Monitoring Adherence to HIV Antiretroviral Therapy in Routine Clinical Practice: The Past, the Present, and the Future
verfasst von
David R. Bangsberg
Publikationsdatum
01.05.2006
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 3/2006
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-006-9121-7

Weitere Artikel der Ausgabe 3/2006

AIDS and Behavior 3/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.